Russia’s Sputnik V Vaccine Claims 92% Efficacy in Fighting COVID-19

The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.

RIO DE JANEIRO, BRAZIL - Scientists gave Russia’s Sputnik V vaccine the green light on Tuesday, February 2nd, saying it was almost 92% efficacious in fighting COVID-19, based on peer-reviewed late-stage trial results published in The Lancet international medical journal.

Experts said the Phase III trial results meant the world had another effective weapon to fight the deadly pandemic, and justified to some extent Moscow’s decision to roll out the vaccine before final data had been released.

The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?